639 692
Santis is a company consultant for GlaxoSmithKline, Janssen, Bayer,
Novartis, Pierre Fabre, Astellas, Amgen, Eisai Inc., ESSA, Merck, and
Synthon; has received company speaker honoraria from Pfizer, Takeda,
Sanofi Aventis, Shionogi, Celgene, and Teva OncoGenex; has participated
in trials for Pierre Fabre, Astellas, Exelixis, Bayer, and Roche; has received
fellowship and travel grants from Bayer, Novartis, Ferring, Astellas, Sanofi
Aventis, and Janssen; has received grant and research support from Pierre
Fabre; has received honoraria from AstraZeneca; and is associated with
Amgen. S. Joniau is a company consultant for Astellas, Ipsen, Bayer, Sanofi,
and Janssen; has received company speaker honoraria from Astellas,
Amgen, Bayer, Sanofi, Janssen, and Ipsen; has participated in trials for
Astellas, Janssen, and Bayer; has received fellowship and travel grants
from Astellas, Amgen, Bayer, Sanofi, Janssen, Ipsen, and Pfizer; and has
received grant and research support fromAstellas, Bayer, and Janssen. T.B.
Lam is a company consultant for and has received company speaker
honoraria from Pfizer, GSK, Astellas, and Ipsen. M.D. Mason is a company
consultant for Bristol-Myers Squibb, Janssen, Bayer, Sanofi, and Dendreon
and has received company speaker honoraria from Takeda and Bayer. H.
van der Poel is a company consultant for Intuitive Surgical, has
participated in trials for Astellas and Steba Biotech, has received grant
and research support from Astellas. O. Rouvie`re is a company consultant
for EDAP-TMS, Bracco, and Philips and has received company speaker
honoraria from EDAP-TMS, Bracco and Philips and has participated in
trials for EDAP-TMS and Bracco. T. Wiegel has received company speaker
honoraria from Astellas, Takeda, Hexal, Ipsen, Janssen-Cilac, and Ferring.
N. Mottet has received grant and research support from Takeda
Pharmaceutical, Millenium, Astellas, Pierre Fabre, Sanofi, and Pasteur
and has received honoraria or consultation fees from Takeda Pharaceu-
tical, Millenium, Jansen, Astellas, BMS, Bayer, Ipsen, Ferring, Novartis,
Nucle´tron, Pierre Fabre, Sanofi, and Zeneca. T. Gross, Ann M. Henry and
T.H. van der Kwast have nothing to disclose.
Funding/Support and role of the sponsor:
None.
References
[1]
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.[2]
Mottet M, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treat- ment with curative intent. Eur Urol 2017;71:618–29.[3] Oxford Centre for Evidence-Based Medicine – levels of evidence
(March 2009). Centre for Evidence-Based Medicine Web site.
http://www.cebm.net/index.aspx?o=1025 .[4]
Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146–51.
[5]
Roach III M, Hanks G, T hames Jr H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommenda- tions of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
[6]
Brockman JA, Alanee S, Vickers AJ, et al. Nomogram predicting prostate cancer-specific mortality for men with biochemical re- currence after radical prostatectomy. Eur Urol 2015;67:1160–7.[7]
D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radi- ation therapy. J Urol 2004;172:S42–6, discussion S46-7.[8]
Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760–9.
[9]
Zumsteg ZS, Spratt DE, Romesser PB, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009–16.[10]
Rouviere O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur Radiol 2010;20:1254–66.
[11]
Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post- prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 2010;22:46–55.
[12]
Ceci F, Herrmann K, Castellucci P, et al. Impact of 11C-choline PET/ CT on clinical decisionmaking in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 2014;41:2222–31.
[13]
Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Rela- tionship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 2014;52:725–33.
[14]
Abd-Alazeez M, Ramachandran N, Dikaios N, et al. Multipara- metric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic con- trast-enhanced images. Prostate Cancer Prostatic Dis 2015;18: 128–36.
[15]
Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol 2013;189: 1308–13.
[16]
Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-choline positron emission tomography in recurrent prostate cancer. World J Urol 2013;31:319–23.
[17]
Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014;65:1034–43.
[18]
Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical pros- tatectomy is an independent predictor of biochemical outcome– results of a retrospective study. Int J Radiat Oncol Biol Phys 2009;73:1009–16.
[19]
Goenka A, Magsanoc JM, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 2012;84:112–8.
[20]
Soto DE, Passarelli MN, Daignault S, Sandler HM. Concurrent androgen deprivation therapy during salvage prostate radiother- apy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 2012;82:1227–32.[21]
Shipley WU, Seiferheld W, Lukka H, et al. Report of NRG Oncology/ RTOG 9601, a phase 3 trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with pT2-3pN0 dis- ease and an elevated PSA. Int J Radiat Oncol Biol Phys 2016;94:3.
[22]
Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-spe- cific antigen concentration after radical prostatectomy (GETUG- AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016;17:747–56.
[23]
Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match- controlled multi-institutional analysis. Eur Urol 2012;62:472–87.
[24]
Chade DC, Eastham J, Graefen M, et al. Cancer control and func- tional outcomes of salvage radical prostatectomy for radiation- recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961–71.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 3 0 – 6 4 2
639